TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05187585

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: radiograph interpretation without the support of the RAYVOLVE app
Description: Phase 1 does not involve any intervention: residents, emergency physicians, and radiologists will interpret the x-rays without the support of the RAYVOLVE application.~The emergency physician interprets the x-ray and manage the case as per protocol, all the x-rays will be reinterpreted by the radiologist only later, usually the day after. In case of missed fractures, the physician is notified of the error by the radiologist, and patients will be informed and recalled to the hospital to be reevaluated.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: radiograph interpretation with the support of the RAYVOLVE app
Description: The residents interpret the X-ray with the RAYVOLVE application's support and indicate the presence or not of a fracture without sharing it with the senior emergency physician. A senior emergency physician manages the case as usual, and all the x-rays will be reinterpreted by the radiologist only later, usually the day after. In case of missed fractures, the physician is notified of the error by the radiologist, and patients will be informed and recalled to the hospital to be reevaluated
Study: NCT05106218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurroundScope
Description: The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Laparoscope
Description: The procedure will be performed according to the institution's standard of care, using the Standard laparoscope for visualization.
Study: NCT04697602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stepwise dose titration of febuxostat and low-dose colchicine
Description: Febuxostat 10 mg, orally, once daily, in week 1-4 Febuxostat 20 mg, orally, once daily, in week 5-8 Febuxostat 40 mg, orally, once daily, in week 9-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed dose febuxostat and low-dose colchicine
Description: Febuxostat 40 mg, orally, once daily, in week 1-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
Study: NCT05745610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shen Hai Long Capsule
Description: 3 times/day (9 capsules/day) for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sheng Jing Capsule
Description: 3 times/day (12 capsules/day) for 12 weeks
Study: NCT04299906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solaris Vascular Stent Graft
Description: Solaris Vascular Stent Graft for treatment of Iliac Lesions
Study: NCT05359809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graspin Palmar Reflex Stimulation
Description: The grasping reflex is an involuntary response involving the hands and fingers. flexion-adduction movement. The reflex resembles the grasping movement of the hand. The reflex can be achieved by moving an object distally across the palm.
Study: NCT05285436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CloudCath System
Description: The CloudCath System enables drainage and measures turbidity, reported as a numeric score, in peritoneal dialysate effluent.
Study: NCT05605548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: MitoQ is a mitochondrial targeted antioxidant that can be obtained over-the-counter.
Study: NCT05623072

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: 20 min, 2 milliampere (mA), Anodal tDCS in vmPFC

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: 20 min, vmPFC Sham tDCS
Study: NCT04270136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total mastectomy
Description: breast cancer non conserving surgery
Study: NCT04402346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency-assisted pancreas transection
Description: Transection of the pancreas in distal pancreatectomy by applying a radio frequency device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapler assisted pancreas transection
Description: Transection of the pancreas in distal pancreatectomy by applying a stapler device with/without seamguard
Study: NCT05974007

Intervention type: DRUG
Intervention: Neoadjuvant immunochemotherapy
Description: Patients with operable stage I-III NSCLC who have previously undergone platinum drugs and immune checkpoint inhibitors(Anti PD-1) and then undergone radical surgery

Intervention type: DRUG
Intervention: Neoadjuvant chemotherapy
Description: Patients with operable stage I-III NSCLC who have previously undergone platinum-based chemotherapy regimens and then undergone radical surgery
Study: NCT06099366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interim Maintenance(IM): Vincristine, Methotrexate, Mercaptopurine, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Mecaptopurine: 25mg/m2 Intrathecal Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delayed Intesification(DI): Vincristine, Mercaptopurine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 Dexamethasone 10mg/m2 Intrathecal Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delayed Intesification(DI): Vincristine, Mercaptopurine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 Dexamethasone 10mg/m2 Intrathecal Methotrexate
Study: NCT05352165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard long-term therapy
Description: The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard long-term therapy
Description: The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard long-term therapy
Description: The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard long-term therapy
Description: The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard long-term therapy
Description: The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.
Study: NCT06099366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delayed Intesification(DI): Vincristine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 100mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delayed Intesification(DI): Vincristine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 100mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 Methotrexate 20mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
Study: NCT05352165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard long-term therapy
Description: The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.
Study: NCT05605548

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A look-alike inactive substance, a sugar pill
Study: NCT04759313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Image Narrative
Description: Each participant will take part in a 5-week program of weekly 1-hour telehealth sessions with the PI or a social work PhD student facilitator trained in the INI by the PI.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Image Narrative
Description: Each participant will take part in a 5-week program of weekly 1-hour telehealth sessions with the PI or a social work PhD student facilitator trained in the INI by the PI.
Study: NCT05877703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: close kinetic chain exercises
Description: CKC include mini squats, leg press, step-up and step-down, wall slides etc along with their respective modality as quadriceps drill and static cycle ergometer respectively on grade-3 knee OA patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: open kinetic chain exercises
Description: The distal segment of the body components can move freely during OKC exercise.OKC exercises include quadriceps setting, knee extension in sitting and straight leg raise in lying position; it also includes quadriceps drills as part of OKC exercises
Study: NCT05320380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD123 ADC IMGN632
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD123 ADC IMGN632
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD123 ADC IMGN632
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration/biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration/biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study: NCT06099366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 Methotrexate 20mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 Methotrexate 20mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 Methotrexate 20mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
Study: NCT05484466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZM-H1505R
Description: There are three groups in this study. ZM-H1505R will be used in group A and Group B ，Subjects can use it for 48 weeks Group A: 30 subjects； ZM-H1505R 50 mg QD +ZM-H1505R placebo； Group B: 30 subjects； ZM-H1505R 100 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZM-H1505R
Description: There are three groups in this study. ZM-H1505R will be used in group A and Group B ，Subjects can use it for 48 weeks Group A: 30 subjects； ZM-H1505R 50 mg QD +ZM-H1505R placebo； Group B: 30 subjects； ZM-H1505R 100 mg QD
Study: NCT05320380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given IT
Study: NCT06015568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-129: 1500mg or 2000mg IV Q2W
Description: Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Befotertinib: 75 mg or 100 mg Po QD
Description: The initial dose of Befotertinib is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD.~Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs.
Study: NCT04598230

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participants randomized to this arm will receive up to 20 sessions of evidence based cognitive behavioral therapy (CBT) of extended duration, with more exposure tasks and greater family involvement than has been studied in the past.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participants randomized to this arm will receive up to 20 sessions of evidence based cognitive behavioral therapy (CBT) of extended duration, with more exposure tasks and greater family involvement than has been studied in the past.
Study: NCT05352165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX and standard long-term radiotherapy
Description: FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity
Study: NCT04598230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination therapy (COMB)
Description: Participants randomized to this arm will receive cognitive behavioral therapy comparable to that in the cognitive behavioral therapy arm, plus one of three selective serotonin reuptake inhibitors (SSRI) medications (fluoxetine, sertraline, escitalopram)
Study: NCT04875182

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of Delirium development
Description: Postoperative pain scores of the patients will recorded by using a numerical rating scale.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of Delirium development
Description: Postoperative pain scores of the patients will recorded by using a numerical rating scale.
Study: NCT05690698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quatiapine
Description: Atypical antipsychotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Antipsychotic
Study: NCT05720767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: HMPL-523 is a selective small-molecule SYK inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: HMPL-523 is a selective small-molecule SYK inhibitor.
Study: NCT05352165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX and standard long-term radiotherapy
Description: FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX and standard long-term radiotherapy
Description: FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity
Study: NCT05720767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole is an FDA approved synthetic triazole antifungal agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin is an FDA approved semisynthetic antiobiotic derivative indicated in the treatment of both tuberculosis and meningococcal carrier state
Study: NCT04864678

Intervention type: OTHER
Intervention: Referral to the Young People's Health Service immunisation nurse
Description: Young people who have been referred to an immunisation nurse at the Young People's Health Service.
Study: NCT05082506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher without lifting the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Acupressure
Description: Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher without lifting the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief.
Study: NCT05195268

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracardiac Catheter Ablation
Description: Both arms will receive intracardiac catheter ablation procedures as described.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intracardiac Catheter Ablation
Description: Both arms will receive intracardiac catheter ablation procedures as described.
Study: NCT06326671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Inhalation Powder
Description: It's a generic product of Spiriva HandiHaler.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva HandiHaler
Description: Tiotropium Bromide Inhalation Powder RLD, which binds to M3 receptors, and blocks the action of acetylcholine to relieve spasm of bronchial smooth muscle.
Study: NCT05352165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX and standard long-term radiotherapy
Description: FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX and standard long-term radiotherapy
Description: FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX and standard long-term radiotherapy
Description: FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI and standard long-term radiotherapy
Description: FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI and standard long-term radiotherapy
Description: FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity
Study: NCT06164613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinnamomum Verum oil extract
Description: one capsule of 1000 mg orally of Cinnamomum Verum oil extract per day for 21-28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg PO Canola oil soft gel capsule
Study: NCT05380713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be applied in the neoadjuvant setting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: tremelimumab-durvalumab in adjuvant setting
Study: NCT05484466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ZM-H1505R placebo
Description: There are three groups in this study. ZM-H1505R will be used in group A and Group C ，Subjects can use it for 48 weeks Group A: 30 subjects；ZM-H1505R 50 mg +ZM-H1505R placebo 50mg QD ； Group C: 30 subjects；ZM-H1505R placebo 100mg QD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ZM-H1505R placebo
Description: There are three groups in this study. ZM-H1505R will be used in group A and Group C ，Subjects can use it for 48 weeks Group A: 30 subjects；ZM-H1505R 50 mg +ZM-H1505R placebo 50mg QD ； Group C: 30 subjects；ZM-H1505R placebo 100mg QD

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Baraclude
Description: All subjects were orally administered once a day at night ： Baraclude® 0.5 mg QD，60weeks
Study: NCT05380713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: tremelimumab-durvalumab in adjuvant setting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: tremelimumab-durvalumab in adjuvant setting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: tremelimumab-durvalumab in adjuvant setting
Study: NCT05875246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Micro-interventions
Description: Group 1: No intervention Group 2: Brief stress reduction messages Group 3: App based stress reduction audio activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Micro-interventions
Description: Group 1: No intervention Group 2: Brief stress reduction messages Group 3: App based stress reduction audio activity
Study: NCT05484466

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Baraclude
Description: All subjects were orally administered once a day at night ： Baraclude® 0.5 mg QD，60weeks

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Baraclude
Description: All subjects were orally administered once a day at night ： Baraclude® 0.5 mg QD，60weeks
Study: NCT04992546

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRN473 (SAR444727)
Description: White to off-white gel suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRN473 (SAR444727)
Description: White to off-white gel suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White to off-white gel suspension
Study: NCT05863702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Penny
Description: The chatbot will assist patients who have not been see for cancer follow-up care, with scheduling follow-up appointments, labs, scans, specialty appointments, and monitor compliance with the appointments made.